4 results about "Low intraocular pressure" patented technology

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

The present application relates to the technical field of biological medicine, and in particular to a reagent for regulating an ALKBH5-ABCA1 axis and application of the reagent in preparation of a drug for treating glaucoma, wherein the reagent at least includes any one of a reagent for promoting expression of ALKBH5, a reagent for promoting expression of ABCA1, a reagent for inhibiting expression of METTL3, and a DNA methyltransferase inhibitor for a promoter region of ALKBH5 gene.The present application provides a reagent for targeting activation of ABCA1 or a reagent for specifically targeting delivery of ALKBH5 mRNA to a trabecular meshwork, and the reagents can effectively reverse lipid metabolism defects and significantly reduce intraocular pressure.The present application not only provides a novel treatment target based on epigenetics and metabolism for glaucoma, but also realizes a proof of concept of LNP-mRNA intraocular pressure reduction technology for the first time, and has a very high clinical conversion value.

The utility model discloses a device capable of forming an opening in the trabecular meshwork of the eye, comprising a handle, a cutting element, a sheath tube and a pushing element, the cutting element comprises an elongated rod and two cutting blades, the tail of the elongated rod is fixedly connected with the head of the handle, and the head of the elongated rod is connected with the two cutting blades; the two cutting blades are symmetrically arranged with a predetermined opening, and the head of each cutting blade has a cutting part capable of penetrating into the trabecular meshwork and cutting the trabecular meshwork; the sheath tube is sleeved on the elongated rod and can slide along the elongated rod; the pushing element is connected with the handle and can drive the sheath tube to move towards the direction of the two cutting blades, so that the two cutting blades are closed to each other under the extrusion of the sheath tube to cut the trabecular meshwork, the cut tissue is easy to be peeled off from the trabecular meshwork, the cut part of the trabecular meshwork can form a trabecular meshwork opening, and the aqueous humor in the anterior chamber is promoted to flow out of the trabecular meshwork opening to reduce the intraocular pressure; and the size of the trabecular meshwork opening can be controlled during the cutting process.

Provided are a two-component combination pharmaceutical composition and use thereof, which belong to the field of pharmaceuticals. The pharmaceutical composition comprises: carteolol or timolol, netarsudil, a buffer, a tonicity agent, a pH regulator, a tackifier, and water for injection. By adding the pH regulator to a solution of netarsudil free base and carteolol free base or timolol free base, the problem that netarsudil is immiscible with carteolol or timolol is successfully solved. The preparation process is simple, the intraocular pressure is reduced by means of different mechanisms of action, and the therapeutic effect is significant and precise. The ophthalmic pharmaceutical composition provides the possibility for clinically safe and effective reduction of intraocular pressure and treatment of glaucoma.